Média

Passing on Onxeo’s Extraordinary and Ordinary General Meeting // DANISH TRANSLATION: Forløb af Onxeos ekstraordinære og ordinære generalforsamling

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that the Extraordinary and Ordinary General Meeting, held at the company’s headquarters in Paris, France on April 6, 2016, adopted all of the resolutions recommended by the Board of Directors….read more →

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

Onxeo announces closing of DNA Therapeutics acquisition // DANISH TRANSLATION: Onxeo gennemfører opkøbet af DNA Therapeutics

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has completed the acquisition of DNA Therapeutics and its signal-interfering DNA (siDNA) repair technology and lead product…read more →

Onxeo Announces Establishment of U.S. Subsidiary // DANISH TRANSLATION: Onxeo etablerer amerikansk datterselskab

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the creation of a U.S. subsidiary, based in New York City. The company also announced that experienced industry executive…read more →

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting // DANISH TRANSLATION: Onxeo-poster godkendt til præsentation på årsmødet i AACR: Livatag® demonstrerer unik virkningsmekanisme

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that a poster demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the…read more →

Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016 // DANISH TRANSLATION: Onxeo ordinær og ekstraordinær generalforsamling den 6. april 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) –  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on April 6, 2016 at 10.00 AM CET at Onxeo’s headquarters:…read more →